Results 81 to 90 of about 14,371 (140)

EDNRB‐dependent endothelin signaling reduces proliferation and promotes proneural‐to‐mesenchymal transition in gliomas

open access: yesMolecular Oncology, Volume 20, Issue 8, Page 1933-1962, August 2026.
Glioma cells mainly express the endothelin receptor EDNRB, while EDNRA is restricted to a perivascular tumor subpopulation. Endothelin signaling reduces glioma cell proliferation while promoting migration and a proneural‐to‐mesenchymal transition associated with poor prognosis. This pathway activates Ca2+, K+, ERK, and STAT3 signalings and is regulated
Donovan Pineau   +36 more
wiley   +1 more source

Spontaneous Tumor Lysis Syndrome in Blastoid-Variant Mantle Cell Lymphoma: Considerations for the General Internist

open access: yesJournal of Investigative Medicine High Impact Case Reports, 2020
Spontaneous tumor lysis syndrome (SPTLS) is a rare phenomenon that can manifest in rapidly proliferating hematological malignancies and solid tumors prior to initiating cytotoxic therapy.
Vishal Patel MD, Robert Case MD
doaj   +1 more source

miR155, triplicated in Down syndrome, regulates the development of neural stem cells and GABAergic interneurons in Alzheimer's disease mouse and human iPSC models

open access: yesAlzheimer's &Dementia, Volume 22, Issue 8, August 2026.
Abstract INTRODUCTION Dysfunctional microRNAs and GABAergic interneurons are features of Alzheimer's disease (AD). The role of neuronal microRNA155 (miR155), elevated in both AD and Down syndrome (DS), remains unknown. METHODS We utilized in silico analyses of published databases, MIR155‐deleted and ‐overexpressing human induced pluripotent stem cell ...
Xiaodong Zhu   +10 more
wiley   +1 more source

Clinical Validation of a QSP Model for ISB 2001, a Trispecific T Cell Engager to Support Optimal FIH Study Design in RRMM Patients

open access: yesClinical Pharmacology &Therapeutics, Volume 120, Issue 2, Page 452-464, August 2026.
ISB 2001 is a trispecific antibody that binds to two tumor‐associated antigens (TAA), CD38 and BCMA, and crosslinks to CD3 on T cells resulting in T cell‐mediated cytotoxicity of tumor cells expressing these TAAs. ISB 2001 is currently being tested in relapsed and/or refractory multiple myeloma (RRMM) patients in the first‐in‐human (FIH) TRIgnite‐1 ...
Vinu Chandralayam Ayyappa Menon   +11 more
wiley   +1 more source

Spontaneous Tumor Lysis Syndrome due to Uterine Leiomyosarcoma with Lung Metastases

open access: yesCase Reports in Critical Care, 2017
Tumor lysis syndrome (TLS) is an oncologic emergency characterized by a combination of metabolic derangements (hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia) caused by rapid turnover from cell destruction in certain cancers.
Vivek Alaigh, Debapriya Datta
doaj   +1 more source

Thromboinflammatory biomarkers in obstetric pathophysiology: Predictive insights into placental insufficiency and feto‐maternal adverse outcomes

open access: yesClinical and Translational Discovery, Volume 6, Issue 4, August 2026.
Placental insufficiency is a thromboinflammatory disorder driven by angiogenic imbalance, complement activation, endothelial dysfunction and coagulation dysregulation, leading to microvascular thrombosis, impaired uteroplacental perfusion and adverse maternal and fetal outcomes, including pre‐eclampsia, fetal growth restriction and stillbirth. Abstract
Emmanuel Ifeanyi Obeagu
wiley   +1 more source

Spontaneous tumor lysis syndrome in a patient with metastatic prostate cancer

open access: yesMolecular and Clinical Oncology, 2017
Tumor lysis syndrome (TLS) is a life-threatening oncological emergency, with most cases occurring in hematological malignancies following the initiation of treatment. However, on rare occasions, TLS may occur in solid tumors as well. In the present case study, the case is reported of a 56-year-old African-American man who presented with a recent ...
Serling-Boyd, Naomi   +2 more
openaire   +5 more sources

Pure erythroid leukaemia in early infancy: Diagnostic pitfalls and clinical challenges

open access: yes
British Journal of Haematology, EarlyView.
Riccardo De Carli   +5 more
wiley   +1 more source

Venetoclax plus azacitidine, low‐dose cytarabine, aclarubicin, and G‐CSF (VA‐CAG regimen) for newly diagnosed young patients with acute myeloid leukemia: A prospective, multicenter, single‐arm Phase II clinical trial

open access: yesHemaSphere, Volume 10, Issue 8, August 2026.
Abstract We conducted a prospective, multicenter, Phase II study to evaluate the safety and efficacy of venetoclax/azacitidine/low‐dose cytarabine/aclarubicin/granulocyte colony‐stimulating factor (G‐CSF) (VA‐CAG) in young patients with newly diagnosed acute myeloid leukemia (ND‐AML). The VA‐CAG regimen included venetoclax (100 mg/day, Days 1–2; 200 mg,
Xiaoping Li   +36 more
wiley   +1 more source

Simultaneous Leukocytapheresis and Continuous Renal Replacement Therapy for Acute Myeloid Leukemia: A Case Report

open access: yesJournal of Clinical Apheresis, Volume 41, Issue 4, August 2026.
ABSTRACT Hyperleukocytosis in acute myeloid leukemia (AML) could cause life‐threatening complications, including leukostasis and tumor lysis syndrome (TLS). While leukocytapheresis and continuous renal replacement therapy (CRRT) are typically performed independently to maintain hemodynamic stability and manage anticoagulation, their simultaneous ...
Seung Hee Cho   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy